Deal snapshot: Kalytera Therapeutics to Acquire COVID-19 Drug Developer Salzman Group.

MANews-(C)2009-2020

US-based pharmaceutical company Kalytera Therapeutics, Inc. (TSX Venture: KLY) (OTCQB: KALTF) has signed a binding letter of intent to acquire US-based drug developer Salzman Group, Inc., the company said.

Salzman Group is the owner of R-107, a proprietary drug with issued and pending composition of matter and method of...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT